Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

This study has been completed.

Study NCT00136604 Information provided by GlaxoSmithKline

First Received: August 26, 2005 Last Updated: June 12, 2007 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given